SHODH SAGAR®
Journal for Medical Research Advancement
Vol. 1 | Issue 4 | Oct - Dec 2024 | Peer Reviewed & Refereed

Advances in Vaccine Development: Toward a Universal Influenza Vaccine

Dr. Nivedita Devas
Senior Consultant
Hyderabad.

Accepted: 17/10/2024 Published: 31/12/2024 *Corresponding author

How to Cite this Article:
Devas, N. (2024). Advances in Vaccine Development: Toward a Universal Influenza Vaccine. *Shodh Sagar Journal for Medical Research Advancement,* 1(4), 19-23.
DOI: https://doi.org/10.36676/ssjmra.v1.i4.28

Abstract

Influenza remains a significant global health concern, causing seasonal epidemics and occasional pandemics with substantial morbidity and mortality. The effectiveness of current influenza vaccines is limited by the antigenic variability of the virus, necessitating annual updates to match circulating strains. A universal influenza vaccine, capable of providing broad and long-lasting protection against diverse influenza strains, represents a critical goal in public health. Recent advances in vaccine research have brought us closer to this objective by targeting conserved epitopes across multiple influenza strains. This review discusses the latest developments in universal influenza vaccine candidates, including novel antigen design strategies, innovative adjuvant formulations, and advanced delivery systems. Furthermore, we explore the preclinical and clinical studies evaluating the safety, immunogenicity, and efficacy of these next-generation influenza vaccines. While significant challenges remain, such as achieving optimal cross-protection and overcoming regulatory hurdles, the progress in universal influenza vaccine development holds promise for revolutionizing influenza prevention and control strategies.

Keywords: Influenza, cine development, Universal vaccine, Antigenic variability

Introduction

Influenza viruses continue to pose a significant threat to public health worldwide, causing seasonal outbreaks and occasional pandemics with substantial morbidity and mortality. Despite extensive vaccination efforts, the effectiveness of current influenza vaccines remains limited, primarily due to the antigenic variability of the virus. The need for annual vaccine updates to

match circulating strains underscores the ongoing challenge in influenza prevention and control. To address the shortcomings of existing influenza vaccines, there is growing interest in developing a universal influenza vaccine capable of providing broad and durable protection against diverse influenza strains, including seasonal influenza viruses and emerging pandemic threats. Unlike conventional vaccines, which target strain-specific surface antigens, such as hemagglutinin (HA) and neuraminidase (NA), a universal influenza vaccine aims to stimulate immune responses against conserved epitopes shared among different influenza strains.

Recent advancements in vaccine technology and immunology have propelled research efforts toward the development of such a universal vaccine. Novel antigen design strategies, including the identification of conserved regions within viral proteins, such as HA stalk and nucleoprotein (NP), hold promise for eliciting cross-reactive immune responses against multiple influenza strains. Additionally, innovative adjuvant formulations and delivery systems are being explored to enhance vaccine immunogenicity and efficacy., we provide an overview of the latest developments in universal influenza vaccine candidates and their underlying mechanisms of action. We discuss the preclinical and clinical studies evaluating the safety, immunogenicity, and protective efficacy of these next-generation influenza vaccines. Furthermore, we examine the challenges and opportunities in translating experimental findings into clinically viable vaccine products, including regulatory considerations and manufacturing scalability.By advancing our understanding of influenza virus biology and host immune responses, along with leveraging cutting-edge vaccine technologies, we aim to accelerate progress toward the development of a universal influenza vaccine that can provide robust and long-lasting protection against influenza infections. Such a breakthrough holds the potential to revolutionize influenza prevention strategies and mitigate the global impact of this perennial infectious disease.

Despite the significant progress made in influenza vaccine development, several challenges persist. The antigenic variability of influenza viruses, driven by frequent genetic mutations and reassortment events, poses a formidable barrier to achieving universal protection. Seasonal influenza vaccines must be reformulated annually to match the predominant circulating strains, a process that requires timely strain selection and manufacturing scale-up. However, mismatches between vaccine strains and circulating viruses can compromise vaccine effectiveness, highlighting the need for more resilient vaccine strategies. Moreover, the threat of novel influenza strains with pandemic potential remains a constant concern. The emergence

of zoonotic influenza viruses, such as avian influenza A(H5N1) and A(H7N9), underscores the unpredictable nature of influenza pandemics and the importance of preparedness efforts. While rapid response platforms, such as recombinant DNA technology and cell-based vaccine production, have enhanced pandemic vaccine manufacturing capabilities, the development of a universal influenza vaccine offers a proactive approach to pandemic preparedness by providing broad protection against diverse influenza strains.

In recent years, there has been a surge in research funding and collaborative initiatives aimed at accelerating the pace of universal influenza vaccine development. Multidisciplinary approaches, combining structural biology, immunology, and computational modeling, have led to the identification of conserved epitopes and antigenic targets for vaccine design. Furthermore, advances in vaccine delivery systems, such as virus-like particles (VLPs) and nanoparticle-based platforms, offer opportunities to enhance vaccine stability, immunogenicity, and dose sparing. In light of these advancements, there is cautious optimism regarding the prospect of a universal influenza vaccine. However, significant hurdles remain, including the optimization of vaccine formulations, the evaluation of vaccine safety profiles, and the establishment of correlates of protection against influenza infection. Additionally, the equitable distribution and accessibility of universal influenza vaccines, particularly in resource-limited settings and marginalized populations, pose ethical and logistical challenges that must be addressed. we aim to provide a comprehensive overview of the current landscape of universal influenza vaccine research, from basic science discoveries to clinical translation and implementation. By synthesizing the latest evidence and insights from the field, we seek to inform stakeholders, including policymakers, healthcare professionals, and the general public, about the promise and potential of universal influenza vaccines in mitigating the global burden of influenza-related morbidity and mortality.

Conclusion

The pursuit of a universal influenza vaccine represents a critical endeavor in safeguarding public health against seasonal epidemics and pandemic threats. Significant strides have been made in understanding the immunological basis of influenza virus protection and identifying conserved antigenic targets for vaccine development. Novel vaccine platforms and delivery systems offer promising avenues for enhancing vaccine efficacy, durability, and scalability.

While challenges remain, including the optimization of vaccine formulations, the establishment of correlates of protection, and the translation of preclinical findings into clinically effective vaccines, the momentum toward a universal influenza vaccine has never been greater. Collaborative efforts among researchers, industry partners, government agencies, and global health organizations are essential to overcoming these challenges and advancing universal influenza vaccine candidates from the laboratory to the clinic. Moreover, the ongoing COVID-19 pandemic has underscored the importance of pandemic preparedness and the critical role of vaccines in mitigating infectious disease threats. Lessons learned from the development and deployment of COVID-19 vaccines, such as accelerated regulatory pathways, manufacturing innovation, and equitable access initiatives, can inform future efforts to develop and distribute universal influenza vaccines on a global scale. As we look toward the future, it is imperative to sustain momentum and investment in universal influenza vaccine research and development. By prioritizing scientific innovation, interdisciplinary collaboration, and public engagement, we can accelerate progress toward the realization of a universal influenza vaccine that provides robust and long-lasting protection against influenza viruses, ultimately saving lives and reducing the societal and economic burden of influenza-related illness. Together, we can usher in a new era of influenza prevention and control, transforming the landscape of global health for generations to come.

References

Krammer, F., & Palese, P. (2013). Influenza virus hemagglutinin stalk-based antibodies and vaccines. Current opinion in virology, 3(5), 521-530.

Nachbagauer, R., Krammer, F., & Albrecht, R. A. (2018). A Live-Attenuated Prime, Inactivated Boost Vaccination Strategy with Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccines Provides Protection in Ferrets: A Confirmatory Study. Vaccines, 6(4), 70.

Paules, C. I., Sullivan, S. G., Subbarao, K., & Fauci, A. S. (2018). Chasing seasonal influenza—The need for a universal influenza vaccine. New England Journal of Medicine, 378(1), 7-9.

Impagliazzo, A., Milder, F., Kuipers, H., Wagner, M. V., Zhu, X., Hoffman, R. M., ... & Schief, W. R. (2015). A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science, 349(6254), 1301-1306.

Nachbagauer, R., Choi, A., Izikson, R., Cox, M. M., & Palese, P. (2018). Age dependence and isotype specificity of influenza virus hemagglutinin stalk-reactive antibodies in humans. mBio, 9(3), e01992-18.

Stadlbauer, D., Rajabhathor, A., Amanat, F., Kaplan, D., Masud, A., Treanor, J. J., ... & Nachbagauer, R. (2018). Vaccination with a recombinant H7 hemagglutinin-based influenza virus vaccine induces broadly reactive antibodies in humans. mSphere, 3(2), e00583-17.

Kanekiyo, M., Joyce, M. G., Gillespie, R. A., Gallagher, J. R., Andrews, S. F., Yassine, H. M., ... & Ward, A. B. (2019). Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nature immunology, 20(3), 362-372.

Rajao, D. S., & Perez, D. R. (2018). Universal vaccines and vaccine platforms to protect against influenza viruses in humans and agriculture. Frontiers in microbiology, 9, 123.

Carter, D. M., Darby, C. A., Lefoley, B. C., Crevar, C. J., Alefantis, T., Oomen, R., ... & Ross, T. M. (2016). Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses. Journal of virology, 90(9), 4720-4734.

Wheatley, A. K., & Kent, S. J. (2015). Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity. Expert review of vaccines, 14(9), 1227-1239.